Single Cell Genome SequencingMarket - Regional Insights
On the basis of Geography, SingleCell Genome Sequencing Market is segmented into North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa. North America isexpected to be dominant in the market during forecast period. High prevalenceof different types of cancer is witnessed in the U.S. According to a report byAmerican cancer Society, 2018, cancer is the second leading cause of deathafter cardio vascular disease. The report further projected around 1.7 millionnew cases of cancer with around half million deaths, worldwide.
Single cell genome sequencinginvolves isolating a single cell and amplifying and sequencing genes withinthat single cell. Sequencing single cell carries significant importance asindividual cells can differ at great extent in size, protein levels, andexpressed RNA transcripts. These variations could provide important insightsabout several research applications such as cancer research, stem cell biology,immunology, developmental biology, and neurology. Single-cell analysis enablesa closer view of the gene expression of individual cells to understand theirfunctions in complex tissues.
Kits and instruments based ontechnological platform such as Next Generation Sequencing (NGS), polymerasechain reaction (PCR), quantitative polymerase chain reaction (qPCR), and othersprovide high-throughput sequencing of individual cells. Single cell sequencinghas significantly evolved with in-depth understanding of genomes and increasinggenomic research to trace the root cause of many chronic diseases.
Single Cell Genome SequencingMarket Dynamics
Single cell genome sequencing isone of most focused area of research for finding cure for chronic disease suchas cancer as it could help to observe tumor microenvironment. According toWorld Health Organization (WHO), cancer is one of leading non-communicabledisease and second leading cause of death, worldwide. According to a report byInternational Age for Research on Cancer (IARC) in 2012, around 14.1 millionnew cases of cancer were registered with around 8.8 million death and around32.6 million people are living with cancer in the year 2012.
Introduction of new therapies forthe treatment of cancer such as personalized medicine (Immuno-oncology andothers.) is expected to increase the adaption of single cell genomic sequencingfor advancing research in order to observe cellular level changes in cancercells.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2059
Furthermore, application ofsingle cell genomic sequencing in other diseases such as immune system disorderand infectious diseases (Tuberculosis, meningococcal disease, and others.) is akey factor contributing to the market growth. According to statistics given byCenters for Disease Control and Prevention 2017 Vital Signs, around 54.4million U.S. adults suffer from arthritis – which is equivalent to 25% of theU.S. population. Rheumatoid arthritis which is leading autoimmune disorderholds significant share in the overall arthritis prevalence.
Continuous development insequencing technologies is further expected to propel growth of the single cellgenome sequencing market. PCR and next generation sequencing are rapidlyemerging as preferred technology for several applications including single cellgenomic sequencing. For instance, Oxford Nanopore, in 2017, launched twosequencing kits— for direct or PCR cDNA analysis that facilitate easy use andprovide results in reduced time and cost.
Several collaborations amongstcommercial companies and academic and research institutes is expected to propelthe single cell genome sequencing market growth. For instance, in 2015, threesingle cell genomics centers were started in Sweden, Australia and the U.S—withan objective to facilitate R&D activities in single cell genome sequencing.The center in Australia was started with collaboration of Monash University,the University of Melbourne, the University of Newcastle and the HudsonInstitute of Medical Research, and Fluidigm Corporation.
Single cell genome sequencing isutilized by several research institutes and commercial companies for revealingchanges at gene level in single cell which could lead to potential therapiesand access to develop new medicines.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/single-cell-genome-sequencing-market-2059
Moreover, key players that offercutting edge technologies such as NGS technology, q PCR technology and highcommercial and academic research spending are present in the U.S, which isexpected to accelerate the market growth.
Single Cell Genome SequencingMarket - Competitive Landscape
Key players operating in thesingle cell genome sequencing market include, Illumina, Inc., FludigimCorporation, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Inc., QIAGEN,Bio-Rad Laboratories, 10x Genomics, Novogene, BGI, Oxford Nanopore Technologies,and Pacific Biosciences
Companies are focused on newproduct launches and collaborations to extend their market share. For instance,
In January 2018, Illuminalaunched semiconductor-based sequencing system—iSeq 100t that usessequencing-by-synthesis chemistry coupled with CMOS detection technology.
In June 2018, QIAGEN launchedQIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation ofreagents that enables the most accurate microbial community profiling fromcomplex microbiome samples and is used for single cell sequencing.
In January 2018, Thermo FisherScientific and Illumina Inc. entered commercial agreement, under which Illuminacould sell Ion AmpliSeq technology to researchers who conduct scientificstudies on Illumina’s next-generation sequencing (NGS) platforms.
In 2017, Illumina Inc. andBio-Rad Laboratories, Inc. launched the Illumina Bio-Rad Single-Cell SequencingSolution. It is the first next-generation sequencing (NGS) workflow forsingle-cell analysis, which would enable researcher investigate the role ofsingle cells in tissue function, disease progression, and therapeutic response.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2059
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
